Media: Enduring Material
Release Date: May 28, 2024
Expiration Date: June 11, 2025

ACCME 1.25 AMA PRA Category 1 Credit(s)™
EACCME® with 1.0 European CME credits (ECMEC®s)

This discussion aims to raise awareness for the importance of molecular assessments and biomarker-guided treatment selection to help healthcare professionals make better informed and individualized treatment decisions for patients with NSCLC and other cancers.
More

Data have shown that genomic-matched treatments and clinical trials, are often less toxic, more efficacious, and less expensive than traditional cytotoxic chemotherapy and have the potential to achieve better patient quality of life.

It is important for healthcare professionals to understand the process, and rationale, behind the development of targeted therapies as they continue to lead to the integration of genomic-guided therapies in clinical settings.

Available in English.

Register

Sign up to access the webcast

What to expect? Watch our video to learn more.

Watch the video

Our program at a glance

Program Director, Jaime L. Schneider, MD, PhD, is joined by Solange Peters, MD, PhD and Lizza Hendriks, MD, PhD, for this expert discussion.

Time Session Speaker
16:00-16:05 BST Introduction: The era of precision oncology Dr. Schneider
16:05-16:20 BST Biomarker-testing for NSCLC Dr. Schneider
16:20-16:40 BST Evolving landscape of targeted therapies Dr. Hendriks
16:40-16:55 BST Challenges and future directions of biomarker testing Dr. Peters
16:55-17:15 BST Discussion and Q&A All

Clinical experts

Jaime L. Schneider

Jaime L. Schneider, MD, PhD (USA)
Program Director

Massachusetts General Hospital, Harvard University, Boston, MA, USA

Bio
Solange Peters

Solange Peters, MD, PhD (Switzerland)

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Bio
Lizza Hendriks

Lizza Hendriks, MD, PhD (the Netherlands)

Maastricht University Medical Center, Maastricht, the Netherlands

Bio

Target audience

The program will be targeted to healthcare professionals involved in the clinical management of patients with non-small cell lung cancer (NSCLC) including, but not limited to, medical oncologists, pathologists, radiologists, surgeon specialists in lung cancer, cancer care coordinators, lung cancer nurses, lung cancer coordinators, and multi-disciplinary care team coordinators.

Accreditation

Jointly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Springer Healthcare. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All relevant financial relationships have been mitigated.

 

EACCME

The Biomarker-Positive Disease: A Personalized Approach to Selecting Targeted Therapies in Lung Cancer and Beyond, Virtual, United Kingdom 28/05/2024–28/05/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credit(s)™. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Disclosures

In addition to the expert faculty, Postgraduate Institute for Medicine and Springer Healthcare IME planners and staff include Holly Keatts, Judith Mitchek, Maria Glukhovsky, Elizabeth Samander, Alessander Geffner-Smith, and Jennifer Jett. The Planning Committee have no financial relationships to disclose.

All relevant financial relationships have been mitigated.

Jaime L. Schneider

Jaime L. Schneider

Massachusetts General Hospital, Harvard University, Boston, MA, USA

Jaime L. Schneider, MD, PhD, is a medical oncologist at the Massachusetts General Hospital (MGH) Cancer Center specializing the care of patients with thoracic malignancies. Dr. Schneider received her B.A. at Northwestern University and her MD/PhD from the Albert Einstein College of Medicine as part of the Medical Scientist Training Program.

She trained as an internal medicine resident at MGH in Boston, MA as part of the Stanbury Physician-Scientist Pathway. She then completed medical oncology fellowship in the Dana-Farber Cancer Institute/Harvard Cancer Care program. She joined faculty at the MGH Cancer Center and has an active practice caring for patients in the Thoracic Oncology Program.

Jaime L. Schneider, MD, PhD, is also a research scientist at Harvard Medical School where her research is focused on using integrative metabolomics approaches to uncover resistance mechanisms to improve the care of lung cancer patients.

Disclosures
Grant Support
Lung cancer research foundation/ALK positive; A breath of hope lung foundation
Speakers Bureau
Dava Oncology
Consultant/Advisory Board
Cadence CR

Solange Peters

Solange Peters

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

Solange Peters, MD, PhD, is a full professor, and chair of medical oncology and the thoracic malignancies programme in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Prof. Peters specialised in thoracic tumours, lung cancer, and pleural tumours.

Solange Peters, MD, PhD, is currently in charge of teaching and patient care in thoracic malignancies at Lausanne University, where she is building a translational programme in collaboration with the Swiss Federal Institute of Technology and the Ludwig Institute. Her main fields of interest are new biomarker discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy. Her current research projects are mainly focused on innovative immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre and is a co-PI of several other trials. Additionally, she acts as the scientific committee chair and Foundation Council member of the European Thoracic Oncology Platform. She was recently nominated as the Strategic Advisory Board President of the Paris Saclay Cancer Cluster and is part of the Board of Directors of the Swiss National Cancer League.

Prof. Peters has authored more than 500 peer-reviewed manuscripts and book chapters, acts as Associate Editor of the Annals of Oncology, Deputy Editor of Lung Cancer, and serves on the editorial board of several other oncology journals. She was the deputy editor of the Journal of Thoracic Oncology for 10 years. Prof. Peters is active in the educational programmes of the European Society for Medical Oncology (ESMO), where she created the Women for Oncology Committee and for which she was the youngest President ever for an extended time of 3 years 2020-2022, and the International Association for the Study of Lung Cancer (IASLC), where she was a member of the Board of Directors

Disclosures
Grant support
(institutional financial support for clinical trials) sponsored by Amgen, Arcus, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, iTeos, Merck Sharp and Dohme, Mirati, Pharma Mar, Promontory Therapeutics, Roche/Genentech, Seattle Genetics.
Speakers Bureau
AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, GSK, Illumina, Ipsen, Merck Sharp and Dohme, Mirati, Novartis, Pfizer, Roche/Genentech, Sanofi, Takeda.
Consulting / Advisory board
AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BerGenBio, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Nykode Therapeutics, Novartis, Novocure, Pharma Mar, Promontory Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, Seattle Genetics, Takeda.
Board of Director position
Galenica

Lizza Hendriks

Lizza Hendriks

Maastricht University Medical Center, Maastricht, the Netherlands

Lizza Hendriks, MD, PhD, is a pulmonologist specialising in thoracic oncology at the Maastricht University Medical Center, the Netherlands, where she leads the clinical lung cancer research department. Her research line is focussing on brain metastases in patients with lung cancer, neurocognition, oligometastases and locally advanced disease. In 2017-2018, she carried out postdoctoral research on brain metastases and immunotherapy in Gustave Roussy, France under the mentorship of Prof. Besse.

Lizza Hendriks, MD, PhD, is the representative for thoracic oncology in the Maastricht UMC Comprehensive Cancer Cancer, and chairs the Innovative Cancer Diagnostics Therapy group at the School for Oncology and Developmental Biology (GROW) at Maastricht University, where she is also appointed as assistant professor. She is heavily involved in clinical and translational research, and is (local) principal investigator in several phase II and III clinical trials, focusing on (locally) advanced NSCLC and SCLC, targeted treatments and immunotherapies.

She is an active member of Dutch (NVALT, NRS), European (ESMO, EORTC, ETOP, ERS) and global societies (IASLC, ASCO), is secretary of the NVALT studies foundation, vice-chair of the scientific committee of the Dutch Thoracic Group and chairs the EORTC sub-committee on Systemic Treatment for metastatic NSCLC.

Lizza Hendriks, MD, PhD, was the lead author of the revised ESMO Clinical Practice Guidelines on metastatic NSCLC and author of the ESMO Clinical Practice Guideline on SCLC. She is member of the Dutch guideline committees on NSCLC, brain metastases and leptomeningeal metastases. Dr Hendriks is an active program committee member or chair of several national and international conferences and masterclasses. In 2021, she was elected as member of the Young Academy of the Royal Netherlands Academy of Arts and Sciences.

Disclosures
Consulting / Advisory board
(Paid to Institution) Roche/Genentech, Lilly, Pfizer, Takeda, Boehringer Ingelheim, AstraZeneca, MSD, Amgen, Janssen, Novartis, Anheart Therapeutics, Merck
Speakers’ Bureau
Medtalks, Benecke, high5oncology, Medimix, VJOncology.
(Paid to Institution) MSD, Bayer, Lilly, AstraZeneca, Takeda, GSK, Sanofi, Pfizer
Grant Support
(Institutional financial support) Roche/Genentech, AstraZeneca, Boehringer Ingelheim, Takeda, Merck, Novartis, Pfizer, Gilead